NASDAQ:APM - Aptorum Group Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$1.10
▲ +0.05 (4.76%)

This chart shows the closing price for APM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Aptorum Group Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for APM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for APM

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Aptorum Group in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a -100.00% upside from the last price of $1.10.

This chart shows the closing price for APM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Aptorum Group. This rating has held steady since June 2021, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/2/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/2/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/31/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/29/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/27/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/25/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/26/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/13/2020Alliance Global PartnersInitiated CoverageBuyHigh
(Data available from 5/26/2017 forward)

News Sentiment Rating

0.05 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/28/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/27/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/27/2021
  • 1 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
1/26/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/25/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/27/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/26/2022
  • 0 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
5/26/2022

Current Sentiment

  • 0 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Aptorum Group logo
Aptorum Group Limited, a pharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of diseases with a focus on infectious diseases and cancers. Its pipeline enables the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.
Read More

Today's Range

Now: $1.10
Low: $1.01
High: $1.13

50 Day Range

MA: $1.29
Low: $0.95
High: $1.67

52 Week Range

Now: $1.10
Low: $0.86
High: $3.50

Volume

237,460 shs

Average Volume

1,695,887 shs

Market Capitalization

$39.20 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.16

Frequently Asked Questions

What sell-side analysts currently cover shares of Aptorum Group?

The following sell-side analysts have issued research reports on Aptorum Group in the last year:
View the latest analyst ratings for APM.

What is the current price target for Aptorum Group?

0 Wall Street analysts have set twelve-month price targets for Aptorum Group in the last year.
View the latest price targets for APM.

What is the current consensus analyst rating for Aptorum Group?

Aptorum Group currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for APM.

How do I contact Aptorum Group's investor relations team?

Aptorum Group's physical mailing address is 17/F GUANGDONG INVESTMENT TOWER 148 CONNAUGHT ROAD CENTRAL, HONG KONG K3, 999077. The company's listed phone number is 442080929299 and its investor relations email address is [email protected] The official website for Aptorum Group is www.aptorumgroup.com. Learn More about contacing Aptorum Group investor relations.